In this Bioanalysis Zone interview, Pegah Jalili (MilliporeSigma) discusses her current work in analytical R&D of biotherapeutic characterization and quantification, and what she thinks the future looks like for this field of bioanalysis.
Quantitative biodistribution of biotherapeutics at whole body, organ and cellular levels by autoradiography
Tools for mapping and quantifying monoclonal antibody (mAb) and peptide biotherapeutics distribumtion were evaluated by comparing data from three independent methods conducted at the whole body, organ or tissue, and cellular levels.
In this interview, Jun Qu (University at Buffalo; NY, USA) describes his current research focuses, including the technologies he is currently developing. Jun goes on to discuss the challenges involved in implementing sensitive quantifications of biotherapeutics using LC–MS and speculates on the future of the technology.
Available to view on demand. Learn about new UHPLC column technologies and how to exploit them for improved characterization of biomacromolecules.
LC-MS-based approaches are increasingly used for the quantification of proteins in biological samples. Traditionally, triple…
Wacker Biotech GmbH (Jena, Germany) have announced that they will manufacture the active ingredient in the drug Retavase®. This drug has obtained FDA approval to treat acute myocardial infarction in adults.
The first biosimilar for the treatment of breast and stomach cancers has been approved by the FDA, termed Ogivri.
In this commentary, Melanie Anderson discusses the use of paper-based dried sampling technologies and how they can provide opportunities to collect biological samples in the dried state, which involves significantly smaller sample volumes than traditional sample collection approaches.
Lonza (Basel, Switzerland) announce the launch of four new services to expand their early phase biopharmaceutical drug development.
2. Given the complexity and cost of development and manufacturing, are biosimilars more affordable therapeutic options?
In this ‘Ask the Experts’ feature, the experts discuss the complexity and cost of development and whether biosimilars are more affordable therapeutic options.